Corcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in Combination With Eribulin for the Treatment of Patients With Metastatic Triple-Negative Breast Cancer by longitudeadmin | Dec 14, 2015 | Portfolio News
Timothy Henn, Experienced Genomics Diagnostics and Life Sciences Executive, Joins CardioDx as Chief Financial Officer by longitudeadmin | Dec 14, 2015 | Portfolio News
BAROnova Announces Enrollment of First Patients in the ENDObesity II Pivotal Clinical Trial by longitudeadmin | Dec 11, 2015 | Portfolio News
Velicept Therapeutics, Inc. Raises $21 Million in Series B Financing by longitudeadmin | Dec 1, 2015 | Portfolio News
Venus Versa Receives Heath Canada Approval for Skin Rejuvenation and Hair Removal by longitudeadmin | Nov 23, 2015 | Portfolio News
